Intestinal Absorption and First-Pass Elimination of 2', 3'-Dideoxynucleosides Following Oral Administration in Rats
スポンサーリンク
概要
- 論文の詳細を見る
Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides (ddNs), including 3'-azido-3'-deoxythymidine (AZT), 2', 3'-dideoxyinosine (DDI) and 2', 3'-didehydro-3'-deoxythymidine (D4T), following oral administration was investigated in rats. Enzymatic degradation of ddNs in rat intestinal washing and in the intestinal homogenate showed them to be stable in the washing with half lives of more than 140 h, whereas degradation of DDI in the intestinal homogenate was more than ten times as rapid as those of AZT and D4T. Intestinal absorption was studied in three segments of the rat intestine (duodenum, jejunum and colon) using an in situ closed-loop method. The area under plasma ddN concentration curve (AUC) and the residual percent of dose 1 h after dosing indicated a greater absorption of AZT and D4T in the upper intestinal tract than in the colon, very poor absorption of DDI in all segments, and considerable absorption of AZT in the colon. The AUC and the mean residence time (MRT) of ddNs following four different routes (intracenous : i.v., intra portal vein : i.p.v., intra duodenal : i.d. and intra gastric : i.g.) were measured using the in vivo multiple sites of input method in rats. AZT and D4T were rapidly absorbed from the gastrointestinal tract and their bioavabilaility was more than 90%. DDI was less absorbed (33.02%) following i.d. administration compared with AZT and D4T. This poor absorption of DDI was partly attributable to its metabolism in the intestine.
- 日本薬学会の論文
日本薬学会 | 論文
- Rapid and Sensitive Detection of Lophophora williamsii by Loop-Mediated Isothermal Amplification
- マウス摘出下部消化管におけるバニロイド受容体TRPV1の局在とカプサイシン誘起平滑筋収縮作用機序の解明 (生体機能と創薬シンポジウム2008--生命システムにおける情報ネットワークの重要性を解く 講演要旨集)
- NOを介する附子アルカロイド・メサコニチンの内皮依存性血管弛緩作用 (生体機能と創薬シンポジウム2007--創薬研究のルネサンスをめざして 講演要旨集) -- (シンポジウム 気体メディエーターと創薬)
- リンゴ未熟果由来プロアントシアニジンの食物アレルギー感作誘導抑制作用に関する研究 (第15回天然薬物の開発と応用シンポジウム講演要旨集) -- (一般講演)
- 新たな創薬ターゲットとしての膵β細胞機能調節因子 (生体機能と創薬シンポジウム2007--創薬研究のルネサンスをめざして 講演要旨集) -- (シンポジウム メタボリックシンドロームを巡る創薬)